Frontiers in Immunology publishes article about ABNCoV2
Hørsholm, Denmark, April 19, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Immunology published an article about the high level of antibodies induced by the ABNCoV2 COVID-19 vaccine in non-human primates.Excerpt: “In summary, ABNCoV2 induced strong and long-lasting neutralizing antibody responses and efficacy against SARS-CoV-2 in NHP (non-human primates). Together with the comparable variant neutralization capacity seen in the serum of vaccinated animals, these data may indicate a potential for broad protection